BCG
LLY icon

Bravias Capital Group’s Eli Lilly LLY Stock Holding History

Bravias Capital Group’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-300
Closed -$322K – 106
2025
Q4 		$322K Sell
300
-6
-2% -$5.74K 0.19% 80
2025
Q3 		$233K Buy
306
+45
+17% +$33.5K 0.16% 92
2025
Q2 		$203K Buy
261
+10
+4% +$7.77K 0.15% 98
2025
Q1 		$207K Hold
251
– – 0.17% 80
2024
Q4 		$203K Buy
+251
New +$208K 0.17% 97

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bravias Capital Group's LLY Position: Q1 2026 in Review

Bravias Capital Group sold out of Eli Lilly (LLY) in Q1 2026, closing a stake of 300 shares — an estimated $322K sold.

Bravias Capital Group first reported a position in LLY in Q4 2024 and held it in 5 quarters. The position peaked at $322K in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Bravias Capital Group reported no remaining Eli Lilly position as of Q1 2026 after selling out during the quarter.
  • Bravias Capital Group sold 300 Eli Lilly shares in Q1 2026, an estimated $322K.
  • Bravias Capital Group first reported a position in Eli Lilly in Q4 2024 and held it in 5 quarters.
  • Bravias Capital Group's Eli Lilly position peaked at $322K in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Bravias Capital Group's 13F filing for Q1 2026, filed 28 Apr 2026.